Drug profile · INN
bortezomib
BORTEZOM
bortezomib (BORTEZOM) is a 26s proteosome inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — bortezomib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 20
- Programs
- 49
- Data quality
- 0.89
Quick answer
bortezomib (BORTEZOM) is a 26s proteosome inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
26S proteosome inhibitor
Primary target: 26S proteasome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
GSK’s Blenrep returns to the US market after FDA approves resubmission
The FDA has approved GSK’s Blenrep in combination with bortezomib and dexamethasone, clearing the drug’s return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.
GSK Blenrep wins FDA approval in relapsed multiple myeloma
GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.
Pipeline programs
Related & competitor drugs
Related patents
-
US 12331040
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 12005069
Bortezomib compositions
granted -
US 11752164
Bortezomib compositions
granted -
US 11679119
Bortezomib compositions
granted -
US 11672813
Bortezomib compositions
granted -
US 11542526
Oncolytic adenoviral vector and methods of use
granted -
US 11008309
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 10858347
Multicyclic compounds and uses thereof
granted -
US 10399963
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 10167452
Viral purification methods
granted -
US 9994558
Multicyclic compounds and methods of using same
granted -
US 9938258
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
granted -
US 9856241
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 8685734
Viral purification methods
granted -
US 7901921
Viral purification methods
granted -
WO 2008137828
MODÈLE DE MARQUEUR DE MATRICE ET PROCÉDÉS POUR ÉVALUER ET TRAITER L'ARTHRITE ET DES TROUBLES ASSOCIÉS
granted -
US 7429485
Method of producing infectious reovirus
granted -
US 7223585
Viral purification methods
granted -
US 7186542
Method of extracting virus from cell culture
granted -
US 7049127
Method of producing infectious reovirus
expired
Frequently asked questions
What is bortezomib?
bortezomib (BORTEZOM) is a 26s proteosome inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for bortezomib?
BORTEZOM is a marketed brand name for bortezomib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bortezomib?
bortezomib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.